AcrySof IQ Toric A-Code Post-Market Clinical Study

January 10, 2022 updated by: Alcon Research
The purpose of this study is to clinically confirm the rotational stability of a modified AcrySof IQ toric intraocular lens (IOL) in a Japanese population.

Study Overview

Detailed Description

Patients will be examined pre-operatively to up to 3 years post-operatively. One eligible eye will be selected as a target eye for efficacy analysis. If both eyes are eligible, the eye in which the IOL is implanted first will be selected as the target eye.

An interim analysis of results through Visit 4 (Day 120-180) is provided.

Study Type

Interventional

Enrollment (Actual)

125

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hiroshima Prefecture
      • Hiroshima, Hiroshima Prefecture, Japan, 733-0842
        • Alcon Investigative Site
    • Hokkaido
      • Hakodate, Hokkaido, Japan, 040-0053
        • Alcon Investigative Site
    • Miyazaki Prefecture
      • Miyakonojō, Miyazaki Prefecture, Japan, 885-0051
        • Alcon Investigative Site
    • Saga Prefecture
      • Saga, Saga Prefecture, Japan, 840-0831
        • Alcon Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of cataracts with planned cataract removal by phacoemulsification
  • Calculated lens power within the available range
  • Able to sign informed consent and complete all study visits
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Eye conditions as specified in the protocol
  • Uncontrolled glaucoma
  • Pregnancy, current or planned
  • Other protocol-defined exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acrysof IQ Toric A-code IOL
IOL implanted during cataract surgery
Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
Other Names:
  • Models SN6AT3, SN6AT4, SN6AT5
Removal of cataractous lens and implantation of IOL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Absolute Intraocular (IOL) Rotation (Visit 00 to Visit 4)
Time Frame: Visit 00 (Day 1 operative), Visit 4 (Day 120-180 postoperative)
IOL rotation was defined as the IOL axis difference between study visits. A photograph of the eye was taken, and IOL rotation was calculated as the angle between the toric mark on the IOL at Visit 4 and the reference point from Visit 00 (minimum 0 degrees, maximum 180 degrees). A lower value indicates greater IOL stability. No confirmatory hypothesis testing was conducted.
Visit 00 (Day 1 operative), Visit 4 (Day 120-180 postoperative)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Expert Clinical Project Lead, CDMA Surgical, Alcon Research, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2018

Primary Completion (Actual)

May 23, 2019

Study Completion (Actual)

December 17, 2021

Study Registration Dates

First Submitted

November 16, 2017

First Submitted That Met QC Criteria

November 17, 2017

First Posted (Actual)

November 22, 2017

Study Record Updates

Last Update Posted (Actual)

January 19, 2022

Last Update Submitted That Met QC Criteria

January 10, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • ILV814-P001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on AcrySof IQ Toric A-code IOL

3
Subscribe